Navigation Links
OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Date:2/28/2011

BOTHELL, Wash., and VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced today that Scott Cormack, OncoGenex's president and chief executive officer, will take part in a panel discussion on novel cancer treatments at the upcoming RBC Capital Markets Healthcare Conference. The panel discussion entitled, "Cancer Treatments: Under the Radar Unique Late-Stage Opportunities", will take place on Wednesday, March 2, 2011, at 9 a.m. (Eastern Time) in the Holmes I Room of the New York Palace Hotel, in New York City.

A live audio webcast of the panel discussion will be available on Investor Relations page of the OncoGenex website at www.oncogenex.com. A replay of the webcast will also be available on the Company's website for a period of 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceuticals have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer in 2011. OGX-427 is in Phase 2 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
2. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  Diplomat, the nation,s largest ... David Dreyer to the Board of Directors on ... and will also serve as chair of the Audit ... years of accounting, financial, compliance and operating experience in ... has served as chief financial officer, chief operating officer ...
(Date:9/19/2014)... Sept. 19, 2014 Larry J. Merlo , ... ), will speak before the National Press Club in ... company,s recent move to stop selling tobacco products and its ... of health. "Dramatic changes in our health care ... and government," Merlo has said. "CVS Health has a truly ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3
... CHICAGO, March 7, 2012  UHC, an alliance of the ... of a mobile application for Rx LINK ™ , ... insight into their pharmacy price performance. The mobile app ... can be accessed on an Apple iPad. ...
... Drug Discovery Foundation (ADDF) and the Association for ... their fifth annual research award, Frontotemporal Degeneration ... of the program is to accelerate the development ... The ADDF/AFTD program awarded $300,000 to ...
Cached Medicine Technology:UHC Launches RxLINK(TM) Mobile App to Deliver Instant Data Access for Strategic Pharmacy Purchasing 2UHC Launches RxLINK(TM) Mobile App to Deliver Instant Data Access for Strategic Pharmacy Purchasing 3Awards for Drug Discovery Research for Frontotemporal Degeneration Announced 2Awards for Drug Discovery Research for Frontotemporal Degeneration Announced 3
(Date:9/19/2014)... made from the wonder material graphene has been used ... developing cancer. , The biosensor has been shown ... bioassay tests currently in use, and was able to ... the possibility of a rapid, point-of-care diagnostic tool for ... September, in IOP Publishing,s journal 2D Materials . ...
(Date:9/19/2014)... 2014 Follow us on LinkedIn ... medical imaging market, are engineered to enhance the anatomic ... past three decades have expanded the application roles of ... based agents used for over half a century to ... agents have witnessed sea changes, revolutionizing in the process ...
(Date:9/19/2014)... 2014 The Nordic ... style of eating, is making its way ... Doc’s medical weight loss programs, ... good food which leads to improved health. ... patients to understand how diet can impact ...
(Date:9/19/2014)... Recent financial data reveled ... their sales by 7% in the last quarter of ... can be used as a bellwether to determine how ... data has been proven to show trends with shipments ... Other non-trucking data is largely influenced by international and ...
(Date:9/19/2014)... Baltimore, MD & Salt Lake City, UT (PRWEB) September ... pleased to launch the new Activz Greens Smoothie ... Natural Products Expo East, September 18th-20th in Baltimore, ... powder with 8 organic super foods combined in one ... at Natural Products Expo East, September 18th-20th in Baltimore, ...
Breaking Medicine News(10 mins):Health News:Graphene sensor tracks down cancer biomarkers 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3
... Jeffrey M. Bethony, Ph.D., associate professor of Microbiology, ... professor of Microbiology, Immunology, and Tropical Medicine at ... with colleagues from Khon Kaen University in Thailand ... an sensitive and specific biomarker for the detection ...
... being able to mathematically describe the process by which ... its every function, and dysfunction. Such capability holds enormous ... when and where things go developmentally awry and ... of breakthrough is one of the long-term goals of ...
... 29 (HealthDay News) -- Preventive antiretroviral treatment appears to ... against HIV infection, a new study suggests. HIV, ... unprotected sex and contaminated needles. Immediate treatment after ... previous research has found. More recently, several large randomized, ...
... Adrian Mulholland and Dr Christopher Woods from Bristol,s School ... processing units (GPUs) to simulate the molecular processes that ... the H1N1-2009 strain of influenza commonly known as ... in Biochemistry , provide new insight that could ...
... disorders have uncovered insights into those diseases in ... Focusing on the cohesin complex, a group of ... scientists have discovered mutations that disrupt cohesin, causing ... "We are learning more about how these ...
... This release is available in German . ... to establish 20 Collaborative Research Centres (CRCs) by 1 July ... its spring session in Bonn. The new CRCs will receive ... allowance for indirect project costs) for the initial 4-year funding ...
Cached Medicine News:Health News:GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer 2Health News:UC Santa Barbara's Kavli Institute receives 2 grants to explore interface of physics and biology 2Health News:UC Santa Barbara's Kavli Institute receives 2 grants to explore interface of physics and biology 3Health News:Taking Anti-HIV Meds Prior to Exposure May Help Prevent Infection 2Health News:New study shows why swine flu virus develops drug resistance 2Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:DFG establishes 20 new Collaborative Research Centres 2Health News:DFG establishes 20 new Collaborative Research Centres 3Health News:DFG establishes 20 new Collaborative Research Centres 4Health News:DFG establishes 20 new Collaborative Research Centres 5Health News:DFG establishes 20 new Collaborative Research Centres 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: